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Gamma-hydroxybutyrate (GHB) is a naturally occurring compound 
found both in neural (Roth and Suhr 1970) and extraneural tissue (Nelson et 
al. 1981 ). While the endogenous function of peripheral GHB has yet to be 
elucidated, experimentation has found that this compound induces 
anesthesia, and the release of growth hormone and prolactin from the 
anterior pituitary (Oyama and Takiguchi 1970; Takahara et al. 1977). This 
study was undertaken to determine the effect of chronic GHB injections on 
the weight gain of rats during early postnatal development. Acute injections 
were also administered to rats not previously treated with exogenous GHB to 
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ascertain the mechanism of growth hormone release and to determine GHB's 
effect on corticosterone release. 
At the age of 3 days, both male and female rats from the chronic group 
were injected intraperitoneally with 100 mg/kg, 500 mg/kg, or 0 mg/kg of 
GHB. These injections were then performed twice a week for 38 days, with 
the weight being recorded before each injection. Nine days following the end 
of this injection period, those rats that had received 500 mg/kg of GHB, were 
once again injected with of 500 mg/kg of GHB. The plasma was then 
assayed for growth hormone and corticosterone levels. Rats in the acute 
group were injected with 500 mg/kg GHB alone, or in combination with the 
following: 1) chlorpromazine, a dopamine. receptor antagonist, 2) 
cyproheptadine, a serotonin receptor antagonist, or 3) pyridoxine, a 
dopaminergic system stimulator. The plasma growth hormone and 
corticosterone were then determined using ELISA or RIA, respectively. 
Results indicate that chronic GHB administration does not lead to 
significant weight gain for male or female rats. Furthermore, chronic 
administration of GHB leads to a reduction of GHB-induced growth hormone 
release in male rats, possibly due to a receptor down-regulation. In contrast 
to the males, na"ive female rats had no rise in plasma growth hormone 
following GHB injection. Both chlorpromazine and cyproheptadine caused a 
reversal of the GHB-induced rise in plasma growth hormone levels, indicating 
possible action through both the dopaminergic and serotonergic systems. 
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Pyridoxine leads to a decrease in GHB-induced growth hormone, leaving 
some question as to the role of the dopaminergic system in GHB's activity. 
Acute injections of exogenous GHB produced elevated plasma 
corticosterone levels in males and females that were not responsive to the 
dopamine and serotonin antagonists. 
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Introduction 
Gamma-hydroxybutyrate (GHB), shown in Figure 1, is a 4-carbon 
compound containing a hydroxyl and carboxylic acid moiety, on primary 
carbons 4 and 1 respectively. It was originally used experimentally to 
determine if there existed a metabolic or physiological role for butyric acid 
(Laborit 1964). The addition of the hydroxyl group was hoped to delay~-
oxidation, so these roles could be more firmly established (Laborit 1964). It 
was known that this molecule is structurally similar to y-aminobutyric acid 
(GABA), and it was thought that perhaps GHB might be able to cross the 
blood-brain barrier (GABA cannot), and function as a GABA precursor 
facilitating its synthesis in the brain (Laborit 1964; Feigenbaum and Howard 
1996). 
Figure 1. Chemical structure of y-hydroxybutyric acid. 
GHB was found capable of rapidly crossing the blood-brain barrier 
(Laborit 1964; Cash 1996; Feigenbaum and Howard 1996), and was 
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discovered to be a natural metabolite, found in both neural (Roth and Suhr 
1970) and extraneural tissues (Nelson et al. 1981 ). GHB was at one time 
marketed as a health aid to persons with insomnia, and to bodybuilders as an 
inducer of growth hormone release (Chin et al. 1992; Sanguineti et al. 1997). 
Within 3 months of sales, it was banned in California and Florida due to acute 
poisoning (Chin et al. 1992). Ingestion of the drug is reported to give a "high" 
or disoriented effect, and it is easily synthesized illegally by dissolving sodium 
hydroxide in near boiling gamma-butyrol lactone (Sanguineti et al. 1997). 
Metabolism of GHB 
GHB is widely considered to be primarily an endogenous metabolite of 
GABA, and a pathway using this precursor for GHB formation is presented in 
Figure 2. In the brain, GABA is converted into succinic semialdehyde (SSA) 
by the enzyme GABA-transaminase (GABA-T). The SSA can then either be 
oxidized and enter the citric acid cycle (Maitre 1996), or it can be reduced to 
GHB by the action of a cytosolic enzyme, SSA reductase (SSR2) (Rumigny et 
al. 1980). GHB has also been shown to be formed from 1,4-butanediol via 
the action of an alcohol dehydrogenase in neural and extraneural tissues. 
There are two enzymes known to oxidize GHB back to succinic 
semialdehyde, GHB dehydrogenase (GHB-D) and GHB-oxoacid 
transhydrogenase (GHB-T) (Nelson and Kaufman 1994). The former is a 
cytosolic enzyme which catalyzes an NADP+ -dependent reaction that 
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Figure 2. Metabolic pathway for GHB (Redrawn from Vayer et al. 1987). 
Keys to intermediates are listed by number and enzymes are designated by 
letters. 
1) gamma-aminobutyric acid, 2) 1,4-butanediol, 3) gamma-butyrolactone, 4) 
succinic semialdehyde , 5) GHB, 6) succinic acid. 
A) GABA-transaminase, 8) alcohol dehydrogenase, C) peripheral lactonase, 
D) SSA reductase, E) GHB-dehydrogenase, GHB-transhydrogenase, F) 
Succinate dehydrogenase 
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oxidizes GHB and reduces 0-glucuronate to L-gulonate (Kaufman and Nelson 
1981). The latter is a mitochondrial enzyme that oxidizes GHB and 
reduces an oxoacid such as a-ketoglutarate without the NADP+ requirement 
(Kaufman et al. 1988). 
In the brain, GHB-D is the predominant degradative enzyme for GHB 
during the fetal and early neonatal period, while GHB-T takes over this role in 
the later post-natal period. However in peripheral tissue, both enzymes have 
active parts throughout development (Nelson and Kaufman 1994). 
SSA can then be converted to succinate by SSA dehydrogenase, from 
which it can enter the citric acid cycle and be metabolized for energy 
(Kaufman and Nelson 1987). 
Distribution of GHB 
As previously indicated, GHB is found in both neural and extraneural 
locations (Table 1). In the brain, GHB levels vary by region (Snead and 
Morley 1981; Maitre 1997), and the highest concentrations are found in the 
midbrain and in the caudate regions. 
From a developmental standpoint, the highest levels of neural GHB are 
found in neonates (400% higher than in adults) and decline significantly 
through the postnatal period. GABA, succinic semialdehyde dehydrogenase 
(SSDH), and GABA-aminotransferase are at their lowest levels during the 
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prenatal period and increase through postnatal development (Snead and 
Morley 1981 ). In the neonatal brain, the activity of the catabolic enzyme for 
GHB is higher than the activity of the anabolic enzyme (GABA-T) required for 
its synthesis from GABA, indicating that GABA is not the primary source of 
GHB (Snead and Morley 1981). 
GHB exists in various peripheral tissues, with concentrations being 
greatest in brown fat, kidney, heart and muscle (see Table 1.). The high 
levels of GHB found in these organs suggested that it must participate in 
some way in their metabolism (Nelson et al. 1981). GABA is likely not the 
precursor of GHB in extraneural tissue, as it is found in only trace amounts. 
Table 1. Distribution of GHB in neural and peripheral tissues of adult rats 
(Taken from Snead and Morley 1981; Maitre 1997). 
Neural GHB (nmols/g) 
Whole brain 2.29 
Frontal cortex 0.4 
Temporal cortex 5.75 
Hippocampus 1.2 
Striatum 1.8 
Substantia nigra 4.6 
Caudate 11 .4 
Pons-medulla 4.68 
Midbrain 15.0 
Cerebellum 8.48 
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Peripheral GHB (nmols/g) 
Heart 
Kidney 
Liver 
Lungs 
Muscle 
Brown fat 
12.4 
28.4 
1.42 
1.54 
10.2 
37.4 
The GHB Receptor 
Studies indicate that there are two classes of GHB binding sites, one 
with high and the other with low affinity binding (Snead and Liu 1984). In the 
CNS, GHB binding sites seem to exist only on neurons (Maitre 1997). The 
receptor has not been sequenced, although it is known to be composed of 
less than 10% protein, and the remaining structure is mainly composed of 
lipid material (Cash 1996). Binding capacities have been shown to increase 
with Mg2•, although it is not an absolute requirement (Cash 1996). GHB 
membrane binding sites are absent in peripheral tissue (Snead and Liu 1984; 
Cash 1996). 
A study by Snead (1992) on GHB-induced seizures found that rats 
injected with pertussis toxin (PTX) were significantly protected from the 
seizure associated effects of GHB. This suggested that GHB receptors were 
associated with a G protein, as PTX is widely known to be an inhibitor of G 
proteins through ADP-ribosylation (Voet and Voet 1995). Later analyses 
found that in the presence of GTP, but not ATP, the binding affinity of GHB for 
its brain membrane receptor is decreased significantly. This gives evidence 
that the GHB receptor acts through a G protein, because in the presence of 
GTP, the receptor-G protein complex dissociates to a point where a state of 
low affinity receptor binding predominates (Ratomponirina et al. 1995). In 
addition, ADP-ribosylation of the G proteins by PTX prevented them from 
coupling to the GHB receptor. 
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Some researchers have suggested that perhaps GHB is not the 
primary ligand for this receptor, and that the ligand is a molecule yet to be 
elucidated, because some psychotrophic substances that bear no structural 
semblance to GHB have been found to bind to the receptor, with similar 
affinity as GHB (Cash 1996). 
Relationship to GABA 
It is widely held that GHB is a GABA receptor agonist. This concept is 
largely due to the original assumption that GHB is primarily derived from 
GABA. However, there is substantial evidence which suggests that GHB is 
not exclusively derived from GABA endogenously (Feigenbaum and Howard 
1996). A study by Snead et al. (1982) found that inhibiting the formation of 
GABA has no significant effect on GHB levels in the rat brain. GHB has only 
a slight effect on GABAnergic mechanisms, and even this may be indirect 
(Feigenbaum and Howard 1996). Of the two subtypes of GABA receptors, 
GHB is unable to serve as an agonist to the GABAA receptor (Mathivet et al. 
1997), but it is a weak agonist of the GABA8 receptor (Mathivet et al. 1997; 
Nissbrandt and Engberg 1996; Snead 1996). 
Physiological Effects of GHB 
Early research on cats, and later humans, indicated that 
administration of GHB caused depression of the central nervous system 
(Roth and Gairma 1966). However, initial researchers were uncertain if the 
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depressive effects were caused by GHB or its precursor, y-butyrolactone 
(GBL), both of which had been used in the experiments. It was soon 
determined that the physiological effects of exogenously administered GBL 
was attributed to the conversion into GHB by lactonase which is present in 
the blood serum (Roth and Gairman 1966). 
When the amount of GHB in the brain reaches the critical level of 70 
mg/kg, the animals lose their righting reflex and a state of anesthesia ensues 
(Giarman and Roth 1964). The LD50 in rats was shown to be 1.7 g/kg with 
respiratory depression as the cause of death (Laborit 1964). 
During periods of hypoxia, GHB has been demonstrated to increase 
the survival time in the animals studied (Atru et al. 1980), and this action is 
thought to be caused by depressing the cerebral metabolic rate. Under 
extreme anoxic conditions, the most favorable reaction for an animal is the 
reduction of succinic semialdehyde into y-hydroxybutyric acid, leading to the 
formation of NAD+ reserves, which are in short supply during hypoxia and can 
be used to eliminate excess lactate. During exercise, GHB can also be 
converted into succinic acid, which can enter the Krebs cycle upon 
conversion to succinate (Kleimenova et al. 1979). In addition, GHB causes a 
slight drop in body temperature leading to hypothermia, and appears to 
protect against convulsions (Laborit 1964). 
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GHB has also been used experimentally to control alcohol dependence 
since GHB and ethanol share some chemical and pharmacological 
properties. Both are short carbon chains containing hydroxyl groups, and 
both have anesthetic and motor impairing effects. Columbo et al. (1994) 
demonstrated that GHB has a suppressing effect on voluntary alcohol intake, 
and ultimately reduces the amount of ethanol consumption by alcohol 
dependent test animals. Fadda et al. (1989) has found that GHB was able to 
antagonize ethanol withdrawal syndrome in rats. It was demonstrated that a 
significant protection was provided at lower than anesthetic doses. In 
addition, chronic ethanol intake confers tolerance to the sedative and 
anaesthetic effect of GHB. 
Takahara et al. (1977) evaluated the role that GHB played in regulating 
the secretion of pituitary hormones. They found that GHB caused a 
significant rise in the plasma levels of prolactin (PRL) and growth hormone 
(GH) (Oyama and Takiguchi 1970; Takahara et al. 1977). Takahara et al. 
(1977) suggested the release of prolactin might be associated with a possible 
decrease in the release of dopamine from the hypothalamus (see next 
section), as dopamine is also known as prolactin inhibiting factor (PIF) 
(Porterfield 1997). GHB might induce serotonin release from its nerve 
terminals stimulating the release of prolactin and GH (Takahara et al. 1977). 
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It has not yet been determined what long term effects GHB will have on body 
mass (Chin et al. 1992). 
Possible Mechanisms of Actions of GHB on Hormone Release 
While the metabolic and physiological roles of GHB have undergone 
extensive research, many of the mechanisms of its action are not well 
understood (Chin et al. 1992). 
GHB and opium induce similar effects, so researchers hypothesized 
that possibly GHB has some action through the opiate system, possibly as an 
opiate agonist (Feigenbaum and Simantov 1996). However, studies have 
shown that naloxone, an opiate receptor antagonist, could not block the GH 
releasing effect of GHB (Gerra et al. 1995). In addition, there was only 
negligible binding of GHB to theµ, 6 and K subtypes of the opiate receptor at 
any concentration of GHB (Feigenbaum and Simantov 1996). This suggests 
that GHB does not work directly through the opiate system. 
A large body of evidence indicates that GHB might have a strong 
influence on the dopaminergic system by serving as a relatively specific 
inhibitor of dopamine release (Feigenbaum and Howard 1996a). It is known 
that dopamine and its agonists increase the hypothalamic secretion of GHRH 
(Brambilla et al. 1997). GHB is capable of significantly inhibiting impulse flow 
of dopamine through central dopamine neurons, presumably by action on 
their storage granular membranes (Feigenbaum and Howard 1996a; Menon 
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et al. 1974). This inhibition of release resulted in an increase in central 
dopamine (DA) levels (Roth and Suhr 1970). GHB has also been found to 
inhibit rather than enhance dopamine releasing agents, and enhance drugs 
that block dopamine release (Feigenbaum and Howard 1996a). A lengthy 
inhibition of DA release might disinhibit DA autoreceptors resulting in an 
increased expression and activity of tyrosine hydroxylase (the rate-limiting 
enzyme in DA biosynthesis), explaining the increase in DA synthesis that has 
been observed (Roth and Suhr 1970; Feigenbaum and Howard 1996a). 
Research by Volpi et al. (1997) revealed that in patients with 
Parkinson's disease, GHB was still able to cause GH secretion whereas 
GABA was not. This suggests that GHB is not working through a 
GABAnergic pathway as many earlier researchers had assumed, and 
indicates it is acting, in this case, through non-dopamine mediation, such as 
serotonergic neurotransmission or through a cholinergic pathway. 
It has been demonstrated that alpha-2 receptor-stimulated GH release 
is mediated by serotonergic neurotransmission (Conway et al. 1990; Smythe 
et al. 1975). The ability of the serotonin receptor antagonist, metergoline, to 
decrease GHB-induced GH release indicates GHB action may be through the 
serotonergic system (Gerra et al. 1995). Research has shown that GHB 
caused no marked changes in norepinephrine levels (Roth and Suhr 1970), 
but does increase serotonin concentration (Walmeler and Fehr 1978). 
Hedner and Lundborg (1983) found that GHB does not change the 
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endogenous brain concentration of 5-hydroxytryptamine (5-HT, serotonin), 
however it does cause an increase in the rate of 5-HT synthesis and 
degradation (Hedner and Lundborg 1983). Additional research by Vescovi 
and Coiro (1997) found that alcoholics showed a down regulation in the 
serotonin receptor subtype 5-HT1 D. In this instance, GHB is unable to cause 
the release of GH. 
GH is thought to act as an adrenal secretagogue, and cause 
decreased cortisol clearance and metabolism, or possibly a decrease in 
serum cortisol binding globulin leading to increased serum free cortisol in 
humans with elevated GH (Weaver et al. 1994). Previous research on human 
subjects have found that plasma cortisol rose significantly following acute 
GHB administration (Oyama and Takiguchi 1970). In rats, corticosterone 
serves as the primary glucocorticoid instead of cortisol (Griffin and Ojeda 
1996). The effect of GHB on plasma corticosterone levels has not been 
analyzed experimentally in rats. 
The ability of GHB to increase GH levels may be a model to indirectly 
evaluate the hypothalamic action of this drug (Gerra et al. 1995). The 
secretion of GH is under the control of the CNS, through action of two specific 
hypothalmic neuropeptides released from hypophyseal-portal system, GH-
releasing hormone (GHRH), and somatostatin (SS). The actions of GHRH on 
the somatotrophs of the anterior pituitary are stimulatory while the effects of 
SS are inhibitory (Argente et al. 1996; Conway et al. 1990; Muller et al. 1995). 
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Research obiectives 
The primary goals of this research were to examine the action of GHB 
on GH release in rats, as well as to determine if there was an effect on 
plasma corticosterone levels. There were seven major questions asked in this 
research. During the early postnatal period will exogenous GHB 1) increase 
the body mass of rats in a dose dependent fashion, 2) alter basal GH levels, 
and 3) result in alterations in the development of tissues such as the 
adrenals and gonads? In adult rats, 4) what pathway does GHB use to cause 
the release of GH, 5) what effect will GHB have on the release of 
corticosterone, 6) would chronic administration of GHB reduce GHB-induced 
effects, and 7) what response variations exist between male and female rats? 
It is hypothesized in this study, that GHB is able to cause the release 
of GH by increasing modular action of a neurotransmitter on the release of 
GHRH or SS. It is also hypothesized that this release of GH through chronic 
injections of GHB will result in a dose-dependent increase in weight gain in 
both male and female rats. And finally, it is hypothesized that GHB 
administration will result in an increase in plasma corticosterone, similar to 
that seen for cortisol in humans. 
Rationale for Using Neurotransmitter Antagonists and Agonists 
As indicated in the previous sections, GHB has an effect on the levels 
of serotonin and dopamine found in the brain, and both of these 
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neurotransmitters have been shown to influence the release of GH from the 
anterior pituitary. In order to elucidate if the ~HS-induced GH release is due 
to either of these transmitters, the following drugs were used in conjunction 
with GHB: Chlorpromazine, cyproheptadine and pyridoxine. 
Cyproheptadine is a serotonin receptor antagonist (Conway et al. 
1990; Smythe et al. 1975), capable of completely blocking the ability of 5HT 
to elevate serum GH levels in rats at a: dosage of 1 0 mg/kg (Smythe et al. 
1975). If this drug reverses the effect of GHB, it may be assumed 5HT plays 
a role in GHB mediation. 
Chlorpromazine is a dopamine receptor antagonist (Menon et al. 1974; 
Porterfield 1977; Sato et al. 1995) capable of reversing the effects of 
dopamine. If administration of this drug hinders the ability of exogenous GHB 
to elevate serum GH levels, this would indicate dopamine plays a key role in 
GHB mediation. 
Pyridoxine is a drug which helps facilitate the decarboxylation of L-
dopa to dopamine by acting as a coenzyme of Dopa carboxylase. In this 
manner, pyridoxine by elevating dopamine levels (Delitala et al. 1976; Reiter 
and Root 1978), causes a significant rise in GH levels within 60 minutes of 
administration, while simultaneously decreasing prolactin levels (Delitala et al. 
1976). If this drug is capable of enhancing GHB action, it would strongly 
suggest dopaminergic involvement. 
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Methodology 
Animals 
Pregnant rats were purchased from Harlan Sprague Dawley, and 
placed in standard plastic cages with wood chip bedding, and housed in the 
animal care facility in Lappin Hall. The ambient temperature was maintained 
at approximately 22 °C, with a 12-hour lighVdark cycle. Both food and water 
were freely available throughout the experiment. Twenty-four days after birth, 
the juvenile rats were weaned and separated into groups of three. 
Drugs 
Gamma-hydroxybutyrate (sodium salt), pyridoxine, chlorpromazine, 
and cyproheptadine were purchased from the Sigma Chemical Co. 
Cyproheptadine was dissolved in 50% (v/v)·ethanol, and the other three drugs 
were dissolved in physiological saline (0.9% sodium chloride w/v). All drugs 
were at room temperature when administered. 
Chronic Experiment 
The chronic experiment is summarized on the left side of the protocol 
flow chart in Figure 3. On the third postnatal day, the rat pups were sexed 
and weighed. The male and females were divided into three groups, with 
each group containing 5 males and 4 females. The first group received 100 
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mg/kg of GHB, the second received 500 mg/kg of GHB, and the last group 
received of 0.9 % saline, which was used as a placebo. These amounts of 
GHB are well within the range of previous studies (Atru et al. 1980, Colombo 
et al. 1994, Fadda et al. 1989). All injections were performed intraperitoneally 
using a 1 cc syringe with a 27 gauge needle, with a total volume of 0.1 cc. The 
pups were weighed and injected twice a week at approximately 5:00 p.m., for 
' 
a period of 38 days. 
At the end of the 38 days, the rats were euthanized using a small 
animal guillotine, and blood was collected in heparinized 15 ml test tubes. 
The pituitary, left kidney, left adrenal, and left testis/ovary were removed from 
each animal, cleaned of excess fatty tissue, and weighed. 
Acute experiment 
The protocol for the acute experiment is shown in the right side of the 
flowchart in Figure 3. Male and female rats, 7 weeks of age, were divided 
into 5 groups and weighed. The first group received an injection of 
physiological saline only (4 males, 4 females). Group 2 was injected with 
GHB, 500 mg/kg (5 males, 4 females). Group 3 was injected with 
chlorpromazine, 42.6 mg/kg (5 males, 3 females}. Group 4 was injected with 
pyridoxine, 20 mg/kg (4 males, 3 females). The last group, group 5, was 
injected with cyproheptadine, 10 mg/kg (5 males, 4 females). Fifteen minutes 
following the first injection, groups 3-5 received an injection of GHB, 
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I 
•• • ' 
Saline 100 rrg'kg 500 rrg'kg 
(Qmtrol) GHB GHB 
For 38 days, rats were 
Injected and weighed 1EXP~1 twice a week 
•• •• 
I 9 day pause in injections I 
,, 
•• 1~~1 Rats in these two groups were 
sacrificed by guillotine, 
and weights of pituitary, left ~ adrenal, left kidney, and left testis'ovary were detemined. ta! 
• • • • Control I Pyridoxine Ollorprorrazine 11 O;proheptaclne I 
+ 
1 ,s mnutes I 
• ' 
500 I Vehide I 500 500 500 500 
mg/kg rrg'kg rrg'kg rrg'kg rrg'kg 
GHB GHB GHB GHB GHB 
I 70 minute interval I 
Growth hormone assay (ELISA) 
Corticosterone assay (RIA) 
Figure 3. Overview of experimental design. 
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500 mg/kg. The total volume of each injection was 0.2 cc. The initial 
injections were performed at approximately 1 :00 p.m. After a period of 70 
minutes following the GHB injection, the animals were euthanized using a 
small animal guillotine. 
The time period between removing the rat from its cage and sacrificing 
the animal was kept short as possible to prevent a raise in corticosterone 
levels. Blood collected from each rat upon sacrifice was centrifuged to 
separate the plasma. The plasma was then frozen at -20°C until it could be 
analyzed. 
To determine the effect of chronic exposure of exogenous GHB on 
growth hormone release, 5 male and 4 female rats, from the chronic 
experiment also received an injection of GHB, 500 mg/kg/0.2cc. These rats 
had not received GHB for 9 days to determine if there was a long-lasting 
effect. The rats were sacrificed and plasma analyzed in the same manner as 
the rats from the acute experiment. 
Growth Hormone Assay 
Determination of rat plasma growth hormone (rGH) was made using an 
enzyme immunoassay (EIA) system (Amersham International). Plasma 
samples were diluted 1 :5 in assay buffer [0.025M phosphate buffer pH 7.5 
containing 0.1 % sodium azide.] Standards were prepared using serial 
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dilutions (1.6, 4.1, 10.24, 25.6, 64, 160 ng/ml) from a rat growth hormone 
(rGH) stock solution of 400 ng/ml. Fifty microliters of the plasma samples and 
rGH standards were pipetted into individual wells of a microtitre plate, coated 
with anti-goat lgG. An equal volume of antiserum (goat anti-rGH serum) was 
then added to each well, and allowed to incubate at room temperature for 3 
hours. After the incubation period, 50 µI of rGH conjugate was pipetted into 
each well and incubated at room temperature for 30 minutes. The wells were 
then aspirated with a pipette and washed with wash buffer (0.01 M phosphate 
buffered saline pH 7.4 containing 0.2% Tween). A 100 µI aliquot of Amdex 
was then added to each well and allowed to incubate at room temperature for 
30 minutes. Amdex is an amplification reagent that contains a straight chain 
dextran backbone covalently bound to hundreds of horseradish peroxidase 
molecules (Amersham 1996). The wells were again aspirated and washed. 
For the color forming reaction, an 100 µI aliquot of TMB substrate (3,3' ,5,5'-
tetramethylbenzidine/hydrogen peroxide solution, in 20% dimethylformamide) 
was added to each well, and allowed to react at room temperature for a 
period of 30 minutes. The reaction was ended with the addition of 100 µI of 
1 M H2S04. The microtitre plate was then analyzed for optical density (OD) 
using a MR 600 microplate reader (Dynatech Laboratories, inc.) at 450 nm. 
All samples and standards were run in duplicate. 
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The rGH level of each sample was determined using a standard curve 
generated from the optical densities of the known rGH concentrations using 
Microsoft Excel. 
Corticosterone Assay 
Determination of plasma corticosterone was made using a 
radioimmunoassay (RIA) kit (ICN Biomedicals, Inc.). Plasma samples were 
pipetted into glass tubes and diluted 1 :500 in steroid diluent. The tubes were 
then incubated at 98 °C in an lsotemp water bath (Fisher Scientific) for 1 0 
minutes. With the exception of the blank, 100µ1 of anti-corticosterone was 
pipetted to the assay tubes. A 100µ1 volume of corticosterone-3H tracer 
(-10, 000 cpm/1 00µ1) was then pipetted to all of the reaction tubes, and the 
tubes were mixed and incubated at 4°C for 16 hours. 
Following the incubation, 200µ1 of charcoal dextran solution (4°C) was 
added and the tubes were mixed and incubated for 20 minutes. The tubes 
were then centrifuged at 2500 rpm for 15 minutes at 4°C, using a Marathon 
21 K/BR centrifuge (Fisher Scientific). The supernatant was then decanted 
into scintillation vials. A volume of 16 ml of scintillation fluid was then added 
to each vial and counts per minute (cpm) were recorded using a Beckman 
scintillation counter (LS 5801 Series). 
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All samples and standards were run in duplicate. The corticosterone 
levels of each sample was determined using a standard curve generated from 
the cpm of known corticosterone concentrations using Microsoft Excel. 
Statistical Analysis 
Analysis of variance (ANOVA) was used to determine if a significant 
difference existed between groups. In the chronic study, all groups were 
compared to the group receiving the placebo, while in the acute experiment 
groups were compared against those receiving 500 mg/kg of GHB. The 
ANOVA and graphical data were performed using Microsoft Excel. In all 
graphs, points represent the mean ± the standard error value for each group 
indicated. 
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Results 
The administration of 500 mg/kg of GHB in both the chronic and acute 
experiments was observed to produce an anesthetic effect immediately 
following the injections. This sedative state lasted for approximately two 
hours. 
Chronic Experiment 
The effect of chronic GHB injections on male and female rats are 
shown in Figures 4 and 6 respectively. To eliminate the possibility that 
discrepancies in the starting weights of the animals had some impact on the 
study, each day the animals were weighed, the weights were standardized by 
simply dividing by the starting weight of each animal. This information is 
shown in Figures 5 and 7. 
For both the males and females, analysis of variance revealed no 
significant difference between the groups injected with GHB, both 100 mg/kg 
and 500 mg/kg, and the control group (F<5.3, p>0.05). However, while they 
may have not been significant, different trends do seem to exist between the 
males and females. For the males, the highest weight gain was obs_erved in 
the group receiving 100 mg/kg GHB, and the lowest weight gain was 
observed in the group receiving 500 mg/kg GHB (Day 38, F=0.6727, 
P=0.4358), with the difference growing closer to significant over time. 
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hydroxybutyrate. 
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For the females, injection of both 100 mg/kg and 500 mg/kg led to a 
slight increase in body weight over the group receiving the placebo. 
When the weights of the organs were analyzed, it was found that for 
the males, there was no significant difference between the groups receiving 
GHB, either 100 mg/kg or 500 mg/kg, and those receiving saline (F<5.1174, 
.P>0.05). The mean weights for each group is shown in Table 2. 
Table 2. The effect of chronically administered y-hydroxybutyrate on the 
organ development of male rats. All weights are expressed as grams of 
tissue per kilogram of total animal mass. 
Control 
100 mg/kg 
500 mg/kg 
Pituitary Left Kidney Left Adrenal Left Testis 
0.0334 4.4546 0.1102 5.6247 
0.0343 4.3123 0.1012 5.4714 
0.0337 4.4093 0.0999 5.7095 
For the females, there was also no significant difference in organ 
weights between the groups. The groups receiving 100 mg/kg GHB showed 
, a considerable discrepancy in the weights of the left kidney and left adrenal 
(F=3.8157, P=0.0935; F=1.0451, P=0.3407 respectively) between the groups. 
The mean values for these groups are listed in Table 3. 
Table 3. The effect of chronically administered y-hydroxybutyrate on the 
organ development of female rats. All weights are expressed as grams of 
tissue per kilogram of total animal mass. 
Control 
100 mg/kg 
500 mg/kg 
Pituitary Left Kidney Left Adrenal Left Ovary 
0.0382 4.3301 0.1499 0.3149 
0.0384 4.4137 0.1343 0.3704 
0.0404 4.3599 0.1361 0.3670 
27 
Acute Experiment 
Growth Hormone Assa; 
As shown in Figure 8, administration of GHB in males led to a non-
significant increase of plasma GH to 260 ng/ml from a mean of 176 ng/ml in 
the controls. The male rats receiving the dopamine receptor antagonist 
chlorpromazine had their plasma GH return to the basal level of 175 ng/ml 
(P=0.5195: F=0.4539), and those male rats receiving the serotonin receptor 
antagonist, cyproheptadine, had the plasma GH levels fall to 145 ng/ml (P= 
0.3192; F= 1.128). The rats receiving the Dopa carboxylase coenzyme, 
pyridoxine, had their plasma GH fall to 32 ng/ml (P=0.0983; F=3.636). 
For male rats that had received chronic injections of GHB throughout 
their post natal development, administration of 500 mg/kg of GHB did not 
produce an increase in plasma GH, while an elevation of plasma GH did 
occur in the male na'ive rats receiving the first injection (500mg/kg) of GHB 
(P=0.1166; F=3.094). 
As indicated in Figure 9, GHB administration to female rats did not 
cause the increase in plasma GH as seen for the males. Instead GH levels 
fell from 176 ng/ml in the control to 115 ng/ml (P=0.2421, F=1.684). 
Compared to the controls, non-significant reductions in plasma GH levels in 
female rats were observed following acute injections of chlorpromazine [95 
ng/ml (P=0.5010, F=0.5254)], cyproheptadine [83 ng/ml (P=0.2394, 
F=1.706)], and pyridoxine [78 ng/ml (P=0.2189, F=1.975)]. 
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Figure 9. Plasma growth hormone levels of female rats in response to 500 mg/kg of y-hydroxybutyrate alone or 
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For the female rats that had received chronic injections of GHB, the 
acute administration of the drug caused virtually no change in plasma GH 
levels compared to that of the control group, and had a P-value of 0.1397 and 
F-value of 2.896 compared to the na"ive group receiving GHB. 
Corticosterone Assay 
As shown in Figure 10, administration of GHB to male rats, caused a 
tremendous increase in plasma corticosterone levels, when compared to 
saline-injected controls. This increase from 19 ng/ml to 431 ng/ml was 
significant (P=0.0009, F=37.215). This effect was not abated by any of the 
drugs given in combination, and in fact all reported levels are higher, although 
not significantly. The group receiving chlorpromazine had a mean plasma 
corticosterone level of 464 ng/ml, while the group receiving cyproheptadine 
had a concentration of 580 ng/ml (P=0.0869, F=3.959). The final group 
receiving pyridoxine had a plasma corticosterone level of 512 ng/ml. All 
groups were significantly elevated from the controls, but there were no 
significant differences between the treatment groups. 
For the male rats that had received chronic injections of GHB, the 
acute administration of the drug (500 mg/kg) resulted in the same increase in 
plasma corticosterone, 483 ng/ml, as seen in the na"ive rats that received the 
500 mg/kg dosage (see Figure 10). 
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As illustrated in Figure 11, the administration of 500 mg/kg of GHB to 
female rats caused a significant rise in plasma corticosterone as seen in the 
male rats, which had received the 500 mg/kg dosage (P=0.0004, F=50.762). 
The addition of the serotonin and dopamine receptor antagonists and the 
coenzyme for Dopa carboxylase did not alter the effect of GHB. The female 
groups receiving chlorpromazine, cyproheptadine, and pyridoxine had mean 
plasma corticosterone concentrations of 555, 776, and 670 ng/ml 
respectively. 
Unlike the males however, the female rats that had received chronic 
injections of GHB, had a significantly reduced effect on GHB induced 
corticosterone release, 103 ng/ml (P=0.0153, F=11.268). This was an 80% 
reduction. 
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Discussion 
Previous research has indicated that GHB leads to the release of GH 
(Oyama and Takiguchi 1970; Takahara et al. 1977), a hormone that has a 
definite growth promoting function (Griffith and Ojeda 1996). As indicated in 
Figure 5, chronic injections of y-hydroxybutyrate did not result in ,any 
significant increases in the masses of developing male rats. In fact, the group 
receiving the highest dosage, 500mg/kg, had the smallest amount of total 
body mass. Failure to measure a significant increase in mass may be due to 
several factors. GH is known to be released endogenously in a pulsatile 
manner (Jaffe et al. 1998). Chronic injections of GHB, as were performed in 
this research, may lead to an inability of the drug to stimulate GH release, 
therefore consecutive injections could not result in additional growth. 
Evidence for this is shown in Figure 8, in which male rats that had previously 
been injected chronically (indicated on the bar graph as chronic) with GHB for 
a period of 38 days failed to exhibit a rise of plasma GH in response to a 
acute injection of 500 mg/kg of GHB. This effect may be caused by the large 
dose of GHB leading to a down regulation of GHB receptors, or perhaps by a 
down regulation of an intermediate's receptors in the pathway, such as 
dopamine or serotonin. Recent research by Ratomponirina et al. (1998) 
found that chronic peripheral administration of 500 mg/kg of GHB rapidly 
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down-regulates GHB receptors in rats. This effect is long lasting or possibly 
even permanent, since the rats in the group chronically injected with 500 
mg/kg of GHB had not been injected for a period of 9 days before the acute 
portion of the experiment. It is of interest to note that the male rats achieving 
the highest amount of weight gain were those receiving 100 mg/kg. While not 
statistically significant, weight gain was higher in this group than the control. 
This suggests that perhaps at this lower dosage, chronic injections do not 
lead to receptor down regulation. 
For the chronically treated females (Figure 7), administration of both 
the 100 and 500 mg/ml concentrations of GHB resulted in slight increases in 
mass over time, 6.6 and 3.9 % respectively. This is interesting since acute 
administration of GHB in female rats did not result in elevated growth 
hormone levels (see Figure 9). 
In an effort to elucidate the mechanism of action by which GHB causes 
the release of GH, the effects of chlorpromazine and cyproheptadine were 
determined. In both male and female rats, each of these drugs caused a non-
significant decrease in the GH release induced by GHB (Figures 8 and 9). 
The dopamine antagonist chlorpromazine led to 33% and 17% reduction of 
GHB induced GH release in males and females respectively, whereas, the 
serotonin antagonist cyproheptadine resulted in 44% and 28% reductions in 
males and females respectively. Such reductions in GH release caused by 
these antagonists suggest both dopamine and serotonin are involved in the 
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mechanism involved in y-hydroxybutyrate's GH releasing activity, with 
serotonin having a more prominent role as in the case of normal basal 
secretion (Conway et al. 1990). 
Pyridoxine (Vitamin B6) is metabolized in vivo to pyridoxal-5'-
phosphate which can function as a cofactor for dopa decarboxylase which 
converts L-dopa to dopamine (Delitala et al. 1976; Geraldet al. 1982). The 
effect of 20 mg/kg of this cofactor on GHB induced GH release is intriguing. 
In males, the drug caused a 88% reduction in GH release, and a 32% 
' 
reduction in females. This result is quite unexpected since pyridoxine 
produces the release of growth hormone in normal human subjects (Delitala 
et al. 1976). A possible explanation is that pyridoxine has a more rapid effect 
on G H release than does G HB, and by the time the serum was assayed, the 
hormone may have been cleared from the plasma. However, in humans the 
maximum GH peak occurs more rapidly as a result of GHB injection than by 
pyridoxine injection (Delitala et al. 1976; Takahara et al. 1977). In rats, growth 
hormone has a plasma half life of 5-6 minutes (Badger et al. 1991; Goya et al. 
1987) so if pyridoxine does cause a rapid plasma GH surge, it may be cleared 
before the analysis took place. These results coincided with past research 
that has found GHB inhibits rather than enhances dopamine releasing agents 
(Feigenbaum and Howard 1996a). If this is the case, the reduction in GH 
secretion caused by chlorpromazine may just be due to action on the normal 
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pathways for basal GH release, as opposed to action on the GHBnergic 
system. 
Further research should be devoted to determining possible action by 
the adrenergic and cholinergic systems on the GHB pathway. Evidence 
suggests that, in normal conditions, the catecholaminergic and cholinergic 
systems stimulates GH secretion by releasing GHIH and inhibiting SS, and 
the release of adrenaline regulates its pulsatile secretion by action on its 
alpha and beta receptors (Argents et al. 1996; Muller et al. 1995). 
The discrepancies between the male and female responses to GHB is 
quite intriguing, and is not easily explained, since previous research on this 
subject has been performed almost exclusively on males. One explanation is 
the sexual dimorphism in the regulation of GH secretion that exists between 
normal male and female rats (Jaffe et al. 1998). Males tend to have large 
infrequent pulses, predominately during sleep, whereas females have smaller 
more uniform pulses throughout the day (Jaffe et al. 1998; Muller et al. 1995). 
This difference is thought to be caused primarily by the more prominent role 
of hypothalamic somatostatin (SS) in males than in females (Jaffe et al. 
1998). 
GHB was found in this research to have the ability to increase the 
concentration of plasma corticosterone in both male and female subjects by a 
factor of 10-20 fold (Figures 10 and 11 ). The mechanism for this release is 
not known. However, it is probably not due to the release and consequent 
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action of growth hormone as described by Weaver et al. (1994), since the 
females without the increased GH levels also had this elevated corticosterone 
release. GHB may again be acting in the hypothalamus, causing the release 
of corticotropin-releasing hormone (CRH) which could in turn release 
adrenocorticotropin hormone (ACTH) from the anterior pituitary, and 
ultimately cause the release of corticosterone from the adrenal gland. CRH 
secretion from the hypothalamus has been found to be stimulated in response 
to-norepinephrine, acetylcholine, serotonin, and dopamine (Calogero et al. 
1988; Calogero et al. 1989a; Calogero et al. 1989b). Caloogero et al. 1988 
also suggests that CRH secretion is weakly stimulated by epinephrine and 
dopamine. However, when used in combination with GHB, the dopamine and 
serotonin receptor antagonists, chlorpromazine and cyproheptadine, were 
unable to prevent the GHB induced corticosterone release, indicating these 
two particular neurotransmitters appear not to be involved in GHB's 
corticosterone releasing process. 
Another possible mechanism to explain the elevation of corticosterone 
is that GHB could be prompting the release of ACTH by acting directly on 
corticotrophs in the anterior pituitary. Finally, GHB may be acting directly on 
the cells of the adrenal cortex causing the release of corticosterone. These 
possible modes of stimulation were not studied in this research. 
For the male rats, chronic injection of GHB had no effect on sensitivity 
for animals to release corticosterone (Figure 10). For the females however, 
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chronic administration of GHB decreased the drug's ability to release 
corticosterone by 80% (see Figure 11 ). A study by Ogilvie and Rivier (1997) 
found that female rats secrete more ACTH and corticosterone than male rats 
in response to the same amount of ethanol. This effect appears to be · 
dependent on the sex hormone estradiol (Nowak et al. 1995; Ogilvie and 
Rivier 1997). If this increased ACTH release also holds true for GHB, then 
perhaps chronic injections of the drug would result in a more rapid ACTH 
receptor down regulation in female rats than males. 
Conclusion 
The primary goals of this research were to examine the action of GHB 
on GH and corticosterone release in both chronic and acute experiments. 
While the receptor antagonists for the neurotransmitters serotonin and 
dopamine were able to reduce GHB effects, results indicate that GHB did not 
significantly stimulate GH secretion in either sets of experiments at the doses 
of 100 mg/kg and 500 mg/kg used in this research. Consequently, there was 
no dose dependent weight increase caused by this drug. However, injections 
of GHB did cause significant increases in plasma corticosterone. 
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